CSIMarket
 


Liquidia Corporation  (LQDA)
Other Ticker:  
 
 

LQDA's Net Income Growth by Quarter and Year

Liquidia's Net Income results by quarter and year




LQDA Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -27.45 -6.53 -11.56 -16.09
III Quarter September -15.79 -9.09 -7.28 -14.97
II Quarter June -23.52 -9.45 -6.55 -13.92
I Quarter March -11.75 -15.94 -9.18 -14.79
FY   -78.51 -41.01 -34.57 -59.77



LQDA Net Income fourth quarter 2023 Y/Y Growth Comment
Liquidia Corporation in the fourth quarter 2023 recorded net loss of $ -27.45 millions.

According to the results reported in the fourth quarter 2023, Liquidia Corporation achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Liquidia Corporation' s Net Income no change of % ranks overall at the positon no. in the fourth quarter 2023.




LQDA Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Liquidia's fourth quarter 2023 Net Income $ -27.45 millions LQDA's Income Statement
Liquidia's fourth quarter 2022 Net Income $ -6.53 millions Quarterly LQDA's Income Statement
New: More LQDA's historic Net Income Growth >>


LQDA Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Liquidia's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LQDA's IV. Quarter Q/Q Net Income Comment
IV. Quarter 2023 accomplishment of -27.45 millions by Liquidia Corporation come out even more unfavourable if you take a look at -15.79 millions net loss a quarter before.

Within Major Pharmaceutical Preparations industry Liquidia Corporation achieved highest sequential Net Income growth. While Liquidia's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LQDA's IV. Quarter Q/Q Net Income Comment
Current net loss of -27.45 millions by Liquidia Corporation appear even less good considering the net loss -15.79 millions a quarter before.

Within Major Pharmaceutical Preparations industry Liquidia Corporation achieved highest sequential Net Income growth. While Liquidia's Net Income growth quarter on quarter, overall rank is .


Liquidia's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Income 12 Months Ending $ -78.50 $ -57.59 $ -50.89 $ -36.82 $ -41.02
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Liquidia Corporation' has realized cumulative trailing twelve months net loss of $ -79 millions in the Dec 31 2023 period.
The business is detiriorating as the cumulative net loss is becoming larger from $ -57.59 millions for the period from Sep 30 2023 to Dec 31 2022 and $ -46.045117 millions for the twelve months ending in the quarter Dec 31 2022 Kaden Hall mentioned.

Liquidia Corporation achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Liquidia Corporation' has realized cumulative trailing twelve months net loss of $ -79 millions in the Dec 31 2023 period.
The situation is worsening as the cumulative net loss is becoming larger from $ -57.59 millions in TTM ending quarter Sep 30 2023 and $ -46.045117 millions for the twelve months ending in the quarter Dec 31 2022.

Liquidia Corporation achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
LQDA's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for LQDA's Competitors
Net Income Growth for Liquidia's Suppliers
Net Income Growth for LQDA's Customers

You may also want to know
LQDA's Annual Growth Rates LQDA's Profitability Ratios LQDA's Asset Turnover Ratio LQDA's Dividend Growth
LQDA's Roe LQDA's Valuation Ratios LQDA's Financial Strength Ratios LQDA's Dividend Payout Ratio
LQDA's Roa LQDA's Inventory Turnover Ratio LQDA's Growth Rates LQDA's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2023
Docgo Inc 515.60%$ 515.603 millions
Insulet Corporation507.65%$ 507.647 millions
Kiniksa Pharmaceuticals ltd 465.73%$ 465.725 millions
Organon and Co 405.56%$ 405.556 millions
National Healthcare Corp401.70%$ 401.704 millions
Inspire Medical Systems inc 368.67%$ 368.667 millions
Nature s Sunshine Products inc 348.37%$ 348.369 millions
Progyny Inc 295.25%$ 295.246 millions
Boston Scientific Corporation260.00%$ 260.000 millions
Align Technology inc 196.86%$ 196.862 millions
Alcon inc 190.75%$ 190.746 millions
Dexcom Inc 179.19%$ 179.194 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com